Small Pharma has had its second United States patent granted by the United States Patent Office.
The patent provides protection for a therapeutic composition of a small group of deuterated DMT compounds. It has an expected lifetime of exclusivity until April 2041, which Small Pharma has stated strengthens its intellectual property position in support of its research and development.
CEO of Small Pharma, George Tziras, said: “We have made significant strides this year progressing our research and development programs and in securing key IP to support and protect them.
“We secured eight patent grants so far this year, bringing our total from four to twelve.
“The grant of this second United States patent effectively protects all pharmaceutical formulations of the specified deuterated DMT compounds, enabling us to progress our deuterated pipeline with even greater confidence.”
This patent sits alongside Small Pharma’s existing European-granted patent which provides additional protection for the company’s deuterated pipeline in a core market.
The grant marks the Company’s twelfth granted patent in its psychedelic and non-psychedelic portfolio, which includes over 70 pending applications, and is the second United States patent grant within its psychedelic portfolio.
The company also recently announced the receipt of approval for an interaction study between its DMT candidate – SPL026 – and serotonin reuptake inhibitors (SSRIs).
The UK’s Medicines and Healthcare products Regulatory Authority (MHRA) and Regional Ethics Committee gave Small Pharma approval to initiate a drug interaction clinical trial in the UK, which will assess the interaction between SSRIs and SPL026 in patients with Major Depressive Disorder (MDD).
